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a b s t r a c t 
This paper investigates trends in asthma and COPD by using multiple data sources to help 
understanding the relationships between disease prevalence, morbidity and mortality. GP 
drug prescriptions, hospital admissions, and deaths are analysed at clinical commission- 
ing group (CCG) level in England from August 2010 to March 2011. A Bayesian hierarchical 
model is used for the analysis, which takes into account the complex space and time de- 
pendencies of asthma and COPD, while it is also able to detect unusual areas. Main ﬁnd- 
ings show important discrepancies across the different data sources, reﬂecting the different 
groups of patients that are represented. In addition, the detection mechanism that is pro- 
vided by the model, together with inference on the spatial, and temporal variation, provide 
a better picture of the respiratory health problem. 
© 2016 The Authors. Published by Elsevier Ltd. 
This is an open access article under the CC BY license 
( http://creativecommons.org/licenses/by/4.0/ ). 1. Introduction 
Asthma and chronic obstructive pulmonary disease 
(COPD) are the most common chronic respiratory con- 
ditions worldwide, contributing to heavy social and eco- 
nomic burden ( World Health Organization, 2012 ). 
The number of people suffering from asthma in 2014 
was estimated to be 334 million around the world ( World 
Health Organization, 2014 ) and this number is projected to 
rise to 400 million by 2025. Around 250,0 0 0 deaths per 
year are caused by the disease, with the majority of them 
considered to be preventable ( Masoli et al., 2004 ). COPD 
has a lower prevalence of 64 million people but much 
higher mortality, with 3 million deaths annually, an esti- 
mated 6% of all deaths worldwide. COPD is predicted to ∗ Corresponding author at: Department of Epidemiology and Biostatis- 
tics, MRC-PHE Centre for Environment and Health, Imperial College Lon- 
don, London, UK. 
E-mail address: a.boulieri@imperial.ac.uk (A. Boulieri). 
http://dx.doi.org/10.1016/j.sste.2016.05.004 
1877-5845/© 2016 The Authors. Published by Elsevier Ltd. This is an open access
( http://creativecommons.org/licenses/by/4.0/ ). become the third leading cause of death by 2030 ( World 
Health Organization, 2014 ). In the UK, asthma affects 1 
in 5 households, and COPD is the ﬁfth leading cause of 
death after cancer and cardiovascular disease ( Masoli et al., 
2004 ). 
Asthma and COPD have similarities in symptoms and 
treatment and there may be considerable overlap between 
these conditions making them diﬃcult to distinguish clin- 
ically ( Drazen et al., 2015 ). Asthma commonly starts in 
childhood and is often allergic in origin, while a large 
proportion of COPD is caused by smoking and the con- 
dition starts in mid to later life. Common symptoms in 
both conditions are shortness of breath and wheeze, with 
worsening of symptoms with respiratory infections, with 
similarities in treatments of bronchodilators, steroids and 
antibiotics for infections. Triggers for exacerbations, the 
major determinants of admissions and possibly deaths are 
likely to be inﬂuenced by infectious disease trends and 
by common environmental factors with a spatio-temporal 
structure, such as air pollution ( Eeftens et al., 2012 ). article under the CC BY license 
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 A study of trends of these chronic respiratory diseases
is important, as it allows a better understanding of the
characteristics of the disease, to determine whether health
policies or preventive measures are effective, and to iden-
tify high-risk populations that might require additional
care and treatments. A challenge, however, is the choice of
data to use for asthma and COPD analyses. Studies on mor-
tality ( Sin et al., 2006 ) investigate only the highest degree
of severity and ﬁndings may differ from those for hospital
admissions particularly for asthma ( Hansell et al., 2003 ),
which is a more heterogeneous condition. Most studies
have used data from secondary and tertiary care, such as
hospital admissions and emergency care data, but these
will not capture milder cases seen in primary care. It is
estimated that only 20% of asthmatic patients and less
than half of COPD patients suffer from severe symptoms
( Lindebeg et al., 2006 ). 
A useful addition to asthma and COPD research is the
use of General Practice (GP) drug prescription data which
consist in the numbers of items that are prescribed in Eng-
land by GPs and are dispensed anywhere in UK or Europe.
GP drug prescriptions can be very relevant for asthma and
COPD as these are long-term conditions that are controlled
by regular medication. These capture patients of any sever-
ity of the disease, from mild to severe, and hence they can
provide a general picture of the respiratory health of the
population at small area level. Only a few authors have
used GP drug prescriptions to investigate asthma and COPD
trends ( Hansell et al., 2003; Laurent et al., 2009; Naureckas
et al., 2005; Soﬁanopoulou et al., 2013; Vegni et al., 2005 ).
In addition, the geographical trends of asthma and
COPD have only been studied by a few authors. Hansell
et al. (2003) found COPD mortality, hospital admissions
and GP prescriptions for COPD were higher in urban ar-
eas and northern regions of England, but less clear pat-
terns were seen for asthma in comparisons using age-sex
standardised event ratios. Holt et al. (2011) analysed hospi-
talisations within a Bayesian hierarchical framework, while
other examples include Centers for Disease Control and
Prevention (2008) , Joo et al. (2007) , Lipton and Banerjee
(2006) and Nandram et al. (2000) . Soﬁanopoulou et al.
(2013) explored geographical patterns of GP drug prescrip-
tions, considering the Newcastle and North Tyneside area
in the UK as a study region. Studies ( Hacking et al., 2011;
Hansell et al., 2003; Wells and Gordon, 2008 ) suggest that
there is a signiﬁcant difference of morbidity and mortal-
ity within and between regions of the UK over the last
40 years. This needs to be taken into account in order
to both provide reliable statistical estimates, as well as to
help public health policy makers more clearly identify tar-
get areas with great needs and improve disease prevention
and treatment. 
The objective of this study is to investigate trends in
asthma and COPD at the population level across England
by using multiple data sources to help understanding the
relationships between disease prevalence, morbidity and
mortality. We explore spatial and temporal patterns of GP
drug prescriptions, hospital admissions and deaths, and
we evaluate if different behaviours can be seen for differ-
ent data sources which underline different condition sever-
ity. We also focus on the detection of unusual areas, i.e.characterised by a temporal trend which deviates from
the general one, suggesting the presence of a policy or
an emerged localised factor. In this analysis we combine
information on asthma and COPD, given the similarities
in these conditions, issues distinguishing between them
( Drazen et al., 2015 ) and the fact that the GP prescription
dataset used does not provide information on diagnosis. 
The remainder of the paper is structured as follows.
Section 2 describes the study design and the data sources
used for the analysis, and Section 3 describes the statis-
tical modelling framework. In Section 4 the results of the
study are presented, followed by a discussion, and ﬁnally,
Section 5 summarises the main ﬁndings of the paper, and
suggests recommendations for future research. 
2. Data sources 
To gain a better understanding of asthma and COPD,
we make use of three different data sources: ( i ) General
practice (GP) drug prescription data of treatments used
for these conditions, which capture patients with mild to
severe symptoms and will give a general picture of the
disease prevalence across the study region; ( ii ) Hospital
Episode Statistics (HES) admissions with primary diagno-
sis of asthma or COPD; ( iii ) mortality data with asthma
and COPD disease as cause of death. The latter two data
sources will inform on cases characterised by higher sever-
ity. We are going to describe each data source in the rest
of this section. 
2.1. GP drug prescription data 
The Prescription Cost Analysis (PACT) data are ac-
cessed from the NHS Business Services Authority. These
include the monthly prescriptions of all drugs from 8003
general practices across England from August 2010 on-
wards at a monthly temporal resolution. In this study we
use the prescriptions on Salbutamol, Ventolin and Cle-
nil Modulite,with corresponding British National Formu-
lary (BNF) codes 1011R0AAAPAP, 0301011R0BEAIAP and
03020 0 0C0BPABBF respectively. These account for more
than 90% of the total prescription of short acting beta2-
agonist (SABA), a class of drugs that relieves patients from
bronchospasm which characteristically occurs in acute
symptoms ( Drazen et al., 2015 ). Every GP is part of a local
clinical commissioning group (CCG), which is the author-
ity responsible for local healthcare services including local
hospitals and NHS services, according to the 2012 Health
and Social Care Act. GPs of the same CCG collaborate to
evaluate local needs, monitor services, set priorities and
make area-speciﬁc decisions to promote healthcare ser-
vices for local residents. This suggests that GPs within the
same CCG should share similarities. Therefore, the available
GP data are aggregated at CCG (211 in England) level to be
used for the analysis. The PACT data also contain the num-
ber of patients registered within each GP, with information
on age group and sex. These are also aggregated at CCG
level and they are used for the calculation of the expected
number of drugs which will be the offset for the analysis
of GP drug prescriptions. 
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i 2.2. HES and mortality data 
Health data for England from August 2010 to March 
2011 were obtained from the Small Area Health Statistics 
Unit (SAHSU) at Imperial College London. Hospital Episode 
Statistics (HES) admission data, supplied by the Health and 
Social Care Information Centre contain the number of ad- 
missions with a primary diagnosis of asthma or COPD, and 
may also include readmissions of the same patient. Mortal- 
ity data were also obtained from SAHSU, supplied by the 
Oﬃce for National Statistics (ONS), derived from the na- 
tional mortality registrations. The number of deaths with 
underlying cause of death (UCD) of asthma or COPD was 
collected. International Classiﬁcation of Disease coding ver- 
sion 10 (ICD-10) was used for admission and mortality 
coding throughout this time period and asthma and COPD 
were deﬁned as ICD-10 codes 4 90–4 96. Linkage between 
HES and mortality data to identify individual patients was 
not possible. Population data were also obtained from the 
Oﬃce for National Statistics, with individual-level informa- 
tion on age and sex and these were used for the calcula- 
tion of the expected number of cases. HES, mortality, and 
population data were all aggregated to CCG level. 
We have considered the same time period of August 
2010 to March 2011 across all three datasets. 
3. Statistical analysis 
The analysis is conducted within a Bayesian hierarchi- 
cal framework that takes into account the complex depen- 
dence patterns of asthma and COPD over space and time. 
Bayesian methods have been extensively applied in epi- 
demiological studies, in order to summarise the spatial and 
temporal variations of the disease risk ( Best et al., 2005 ). 
Approaches within the spatio-temporal setting have been 
suggested by many authors ( Abellan et al., 2008; Bernar- 
dinelli et al., 1995; Knorr-Held, 20 0 0; Knorr-Held and Be- 
sag, 1998; Waller et al., 1997 ). 
The spatio-temporal model that we use in this paper, 
known as BaySTDetect, is a recently developed method by 
Li et al. (2012) that is able to estimate spatial and temporal 
patterns, and to also detect areas whose temporal pattern 
deviates from the general one. 
3.1. Model speciﬁcation 
The ﬁrst level of the hierarchical model is given by 
Y it ∼ Poisson (μit E i ) (1) 
where Y it and E i are the observed and expected counts in 
CCG i = 1 , . . . , 211 at time points t = 1 , . . . , 8 , correspond-
ing to months August 2010, September 2010,..., March 2011. 
In the second level of the hierarchy, the rate μit follows 
a mixture of two components as follows: 
log (μit ) = z i log 
(
μC it 
)
+ (1 − z i ) log 
(
μAS it 
)
(2) 
where 
log 
(
μC it 
)
= α0 + h i + γt (Common Model) (3) 
and 
log 
(
μAS it 
)
= u i + k it (Area-Speciﬁc Model) (4) The Common Model (3) consists of spatial and temporal 
effects, h i and γ t respectively, that are combined additively 
on the log scale, thus estimating the temporal pattern to 
be the same for all areas. An overall intercept α0 is also 
included. 
To incorporate unusual temporal patterns that may oc- 
cur in any particular month, we allow for the selection of 
an alternative Area-Speciﬁc Model (4) , which estimates the 
temporal effects k it independently for each area. An area- 
speciﬁc intercept u i is also included in the model. 
In the third level of the hierarchy, priors are speciﬁed 
for all model parameters as follows: 
α0 ∼ U (−∞ , + ∞ ) u i ∼ N (0 , 10 0 0) 
h i ∼ N (v i , σ 2 h ) and v i ∼ ICAR ( W , σ 2 v ) k i,t ∼ ICAR ( Q , σ 2 ik ) 
γt ∼ ICAR ( Q , σ 2 γ ) log (σ 2 ik ) ∼ N (α, β2 ) 
. 
For the Common Model, a spatial convolution prior based 
on the standard Besag–York–Mollie formulation ( Besag 
et al., 1991 ) is assigned to the spatial random effects. This 
combines a spatially structured component that follows a 
conditional autoregressive prior (ICAR) ( Besag, 1974 ), ac- 
counting for spatial correlation in the data, and a spatially 
unstructured component following a Gaussian prior, ac- 
counting for heterogeneity in the data. For the spatial ICAR 
prior, we specify the neighbourhood structure by deﬁning 
an adjacency matrix W of size N × N such that the diago- 
nal entries w i, j = 0 and the off-diagonal entries w i, j = 1 if 
areas i and j share a common boundary, and 0 otherwise. 
The temporal effects are assigned the temporal analogue of 
the ICAR prior, thus accounting for the temporal correla- 
tion in the data. Similar to the spatial ICAR prior, the tem- 
poral neighbourhood structure is deﬁned through a matrix 
Q, where q h,t = 1 if | h − t| = 1 and q h,t = 0 otherwise, with
h and t indexing units of time. For the Area-Speciﬁc Model, 
the same ICAR prior is assigned to the temporal compo- 
nent k it . In addition, a prior is assigned to the area-speciﬁc 
variances σ 2 
ik 
as an extra hierarchical level for identiﬁability 
reasons. For the overall intercept α0 and the area speciﬁc 
intercept u i , vague priors are speciﬁed. 
A weakly informative half Normal prior N(0,1) is as- 
signed to each of the parameters σ h , σ v and σγ ( Gelman, 
2006 ), while a N( α, β2 ) prior is assigned to the log (σ 2 
ik 
) 
with parameters α and β2 following priors N(0, 10 0 0) and 
N(0, 2.5 2 ), based on the speciﬁcation by Li et al. (2012) . As
the latter prior is somewhat informative, sensitivity analy- 
sis is carried out to assess the robustness of the results. 
The model indicator z i follows a Bernoulli (0.95) prior, 
selecting estimates from either the Common Model (z = 1) 
or the Area-Speciﬁc Model (z = 0). The parameter 0.95 re- 
ﬂects our expectations that only a small number of areas 
express an unusual temporal pattern. 
To classify areas as unusual, we use the posterior esti- 
mates of the indicator z i representing how likely it is for 
area i to follow the Common Model, i.e. to exhibit a usual 
pattern in the risks, and we select the ones that satisfy the 
following condition: r j ≤ 0.05, where r j is the j th ordered 
posterior z . 
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 3.2. Applications 
The model is ﬁtted to all three datasets described in
Section 2 . In the prescription model, Y it is the number of
GP drug prescriptions in CCG i at month t and E i are the
expected counts. Appropriate covariates are also included
in (2) to adjust for age and sex. As an indicator of age, we
use the percentage of active population (age group 15 to
64), while as an indicator of sex, we use the male to fe-
male ratio. 
In the admission model, Y it are the observed cases of
asthma and COPD admissions in CCG i at month t and E i
are the expected ones based on age and sex direct stan-
dardisation using the whole of England as standard pop-
ulation. Similarly, in the mortality model, Y it is the ob-
served number of deaths due to asthma or COPD in CCG
i at month t and E i is the corresponding expected num-
ber based on age and sex direct standardisation using the
whole of England as standard population. 
The models are implemented in OpenBUGS using
Markov Chain Monte Carlo (MCMC) integration algorithms
( Gilks, 2005 ). Three chains are run for each parameter
per model with different initial values for 80,0 0 0 itera-
tions, from which 20,0 0 0 are discarded as burn-in, and es-
timates are based on the remaining samples using only
every 5th iteration to limit autocorrelation. The simula-
tions took around 17 h per model on an Intel Xeon pro-
cessor 2.50 GHz with 23.4 RAM. Convergence was assessed
through trace plots, BGR statistic, and Monte Carlo error. 
4. Results & discussion 
4.1. Spatial patterns 
We provide maps of posterior rates to investigate the
geographical patterns of asthma and COPD across the three
different data sources and evaluate whether these share
any similarities or differences. Fig. 1 a shows the residual
relative risk of the spatial component exp( h i ) of the Com-
mon Model (2) for the GP drug prescriptions across Eng-
land during the period August 2010 to March 2011, while
Fig. 1 b and c show the corresponding risk for HES admis-
sions, and deaths respectively. 
A clear pattern is observed across all datasets with a
strong increasing effect from south to north. High risk
is focused mainly on the region that includes Liverpool,
Manchester, Leeds, and Sheﬃeld, as well as on the region
Newcastle and Durham, with the highest risks being ob-
served in the north east of England. Potential shared risk
factors may include deprivation, which is highest in ur-
ban areas of the north-east and north-west, environmen-
tal factors such as air pollution and smoking prevalence
( Andersen et al., 2011; Lopez et al., 2006; Prescott and
Vestbo, 1999 ). The north-west is the areas with the highest
prevalence of smokers ( HSCIC, cited October 2015 ). 
By comparing the risk distribution across different data
sources, we observe that for admissions and deaths, these
are somewhat consistent ( Fig. 1 b and c), while for pre-
scriptions important differences are highlighted ( Fig. 1 a).
This observation is conﬁrmed by the heatmap in Fig. 1 d
which shows the correspondence across the three datasources using the spatial relative risk; the area in light grey
represents the CCGs in England that share a low relative
risk while the area in dark grey represents the ones with
a high relative risk. It is clear that the proportion of areas
with a low/high relative risk across all three data sources is
relatively small compared to the proportion of areas with a
low/high relative risk among HES admissions and mortality
data. The correlation of the latter two was estimated to be
0.77, while the corresponding correlations of GP drugs and
mortality, and GP drugs and HES admissions were close to
0.5. 
Low risk is observed for admissions and deaths ( Fig. 1 b
and c) in the south of England, and in the coastal areas. At
the same time these areas exhibit high prescription rates
( Fig. 1 a). This suggests a number of hypotheses for further
investigation e.g. that higher prescription rates are a causal
factor in lower morbidity and mortality, that there are
more patients with milder disease in the south-east poten-
tially related to lifestyle factors (lower smoking) and en-
vironmental factors (lower air pollution), that deprivation
results in higher morbidity and mortality but lower use of
primary care. Age-sex effects could also explain these dif-
ferences; these are accounted for at an aggregate level for
drugs, through the inclusion of appropriate covariates at
the GP practice level in the model, since information was
not available at an individual level, while direct standardi-
sation was used for admissions and mortality. 
Only a few CCGs in the south appear to have high
admission and mortality rates ( Fig. 1 b and c), including
Portsmouth and Southampton CCGs. Increased smoking
prevalence and high deprivation can be related to this. Un-
like the rest of big cities in England, London appears to
have low prescription rates ( Fig. 1 a) potentially related to
the low number of smokers in the area ( HSCIC, cited Oc-
tober 2015 ). Comparing between mortality and admission
spatial patterns, a stronger south to north effect can be
seen for mortality ( Fig. 1 c), showing the south eastern and
central west parts of England as the least risky for disease
death. Another region which potentially represents a group
of patients with mild symptoms is around the Yorkshire
area, where national parks are, and this area clearly stands
out in the admissions map ( Fig. 1 b). 
4.2. Temporal patterns 
The general temporal patterns in England from August
2010 to March 2011 under the different datasets consid-
ered in the study can be seen in Fig. 2 , which plots the
component exp( γ t ) of the Common Model (2) . 
Generally, there was a seasonal pattern in the monthly
risk for asthma and COPD across all data sources over
the period August 2010 to March 2011 however the
trends show important discrepancies. The highest risk was
recorded around Christmas across all data sources. This is
likely to represent peaks in respiratory infections, espe-
cially inﬂuenza and respiratory syncytial virus (RSV) that
peak around this year. These result in increased respira-
tory symptoms from mild to severe and cause exacerba-
tions of disease that are occasionally fatal ( Fleming et al.,
2015 ). The lowest peak was recorded in August for all
three data sources, a period when people are on holidays,
32 A. Boulieri et al. / Spatial and Spatio-temporal Epidemiology 19 (2016) 28–36 
Fig. 1. Spatial patterns of chronic respiratory disease across England for GP drugs (a), admissions (b), and deaths (c); heatmap showing correspondence 
across the three data sources (d). away from their homes. The raise in the rates across all 
datasets around September coincides with the start of term 
at schools. 
By comparing temporal trends across different data 
sources, we observe that there is a high temporal variation 
for mortality, whereas this is lower for admissions and pre- 
scriptions. Interestingly, a time lag is apparent between ad- 
missions and mortality. The highest peak for admissions is 
December, whereas for mortality is January and this might 
reﬂect the group of admissions which were then followed 
by death. 4.3. Detection of unusual areas 
Finally, we obtain the posterior estimates of the indi- 
cator z i for each model and we classify areas as unusual 
based on the rule described in Section 3.1 . 
For GP drug prescription and mortality data, no areas 
were detected as unusual, meaning that all posterior esti- 
mates of the parameter z i were above our a priori thresh- 
old value of 0.05. When ranking areas by probability, the 
Isle of Wight was the area with the smallest probabil- 
ity of following either the common prescriptions temporal 
A. Boulieri et al. / Spatial and Spatio-temporal Epidemiology 19 (2016) 28–36 33 
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 pattern (with a probability of 0.13), or the common mor-
tality temporal pattern (with a probability of 0.11). Look-
ing at the temporal patterns for this area in Fig. 3 , we see
that for prescriptions, a ﬂat pattern is apparent, indicating
low rates with no peaks throughout the whole time period
( Fig. 3 a), while for mortality, a near exponential increase isFig. 3. Temporal trend across differentobserved, which after December 2010 exceeds the national
death rates importantly ( Fig. 3 c). The corresponding plot
for the admissions shows a stable pattern ( Fig. 3 b), similar
to the one for prescriptions ( Fig. 3 a). 
After investigating the CCG of Isle of Wight, we found
that an intervention was implemented in order to reduce
the high prevalence of long respiratory diseases in the
area, which was combined with an excess expenditure on
respiratory medication. The project entitled ‘Isle of Wight
Respiratory Inhaler Project’, led by the National Institute
for health and Clinical Excellence (NICE), involved train-
ing of healthcare professionals in the use of the inhaler,
patient training, and assessment of the inhaler technique.
According to the results reported in 2009, the costs on
selective beta-agonists fell by 22.7%, the number of pre-
scriptions fell by 25.2%, the emergency admissions due to
asthma were reduced by 50%, and associated deaths by
75% ( NICE, cited October 2015; The Pharmaceutical Journal,
2011 ). 
Given the above, the ﬂat pattern in prescriptions seen
in Fig. 3 a is well supported, as well as the one for admis-
sions ( Fig. 3 b). However, the increasing temporal trend in
deaths in Fig. 3 c which peaks in the last month of the
study period generates questions. Since the ﬁndings re-
ported by NICE consider only asthmatic patients, mean-
ing that COPD patients that use the same medication are data sources for Isle of Wight. 
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Fig. 4. Unusual temporal trends under HES admissions data. not represented, further analysis is required for the CCG 
of Isle of Wight separately on asthma and COPD in or- 
der to understand the underlying causes of the mortality 
trend. Additional data need to be also analysed in order 
to see the progression of the rates long after the interven- 
tion was implemented. Moreover, COPD is often misdiag- 
nosed as asthma due to the similar symptoms that these 
two diseases share, and also depending on the availabil- 
ity of spirometry ( Walker et al., 2006 ). This calls for fur- 
ther investigation into the misdiagnosed cases of COPD as 
asthma in the CCG of Isle of Wight which might be an ad- 
verse effect of the project. 
On the other hand, four areas were detected as unusual 
using a 0.05 threshold level for hospital admissions model: 
Harrow, Hillingdon, Redbridge and Southampton. The time 
plots in Fig. 4 show the temporal trends for each unusual 
area, compared to the general temporal trend. 
As it can be seen, the corresponding areas do not fol- 
low particularly extreme patterns, but there are discrep- 
ancies from the common one that the model identiﬁes as 
important. For instance, although Harrow in general ex- 
hibits lower than the average national admission rates due 
to asthma or COPD, an unusual high peak is observed in 
August, as well as one in November, which months are 
considered safe for the rest of England. Hillingdon, on the 
other hand appears to have an extreme decrease in March 
2011. Redbridge shows a different pattern in prescriptions 
from the other areas in that prescriptions increase in early 
November. London is a city known for its diversity, and for the population movements within it, hence it is not easy to 
make conclusions as to what has happened in those CCGs. 
Factors such as differences in local population characteris- 
tics, or differences in the quality of hospital care and the 
support people receive to manage their condition across 
time could be responsible. 
The fourth area that was detected as unusual in terms 
of admission trends is Southampton. This is one of the 
few areas on the South Coast that show an increased risk 
for severe symptoms and deaths due to asthma and COPD 
( Fig. 1 ). Interestingly, it seems that the low risk observed 
in Fig. 4 from December onwards is the outcome of an in- 
tervention that was implemented in order to address the 
excess number of admissions in the CCG of Southampton. 
Wilkinson et al. (2014) found that 34 patients were respon- 
sible for 22% of the total COPD admissions over a 3-year 
period. The authors present an admission avoidance strat- 
egy that was constructed for this group of patients, and as 
a result the readmission rate fell from 13.4 to 1.9%. 
5. Conclusions & further recommendations 
In this paper we have investigated the spatial and tem- 
poral patterns of asthma and COPD, with a special focus on 
the detection of areas that follow an unusual temporal pat- 
tern compared to the general one, by using effective high 
quality datasets, aggregated by CCG which is meaningful 
for healthcare practices. There are two main conclusions 
we have drawn from our study. 
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 First, we have shown that multiple data sources repre-
senting different degrees of disease severity give a more
comprehensive picture of the respiratory health problem
with potential implications for healthcare. Some similari-
ties across the different datasets both in the spatial and
temporal variation are indicated, however also important
discrepancies are apparent reﬂecting the different groups
of patients that are represented. 
Second, the detection mechanism that is provided by
the model we used, together with inference on the spatial,
and temporal variation, can aid health care professionals
and public health practitioners identify target areas, assess
a policy impact or the quality provided by hospitals, and
hence develop effective prevention programs to improve
population health. 
A strong aspect of the modelling approach is that it
identiﬁes unusual behaviour not only in terms of increased
risk, but also in terms of any risk pattern that deviates
from the expected one. Additionally, it only detects areas
when a certain criterion is met, and the speciﬁcation of
this depends on how conservative we want to be. In the
original paper the model was applied on annual data by Li
et al. (2012) , while here we used monthly data as we were
interested in the seasonal pattern of asthma and COPD.
A great advantage of the additive model speciﬁcation is
that it allows for such ﬂexibility, through the temporal ran-
dom effects which account for unmeasured covariates that
vary across time. Li et al. (2012) chose a Bayesian False
Discovery Rate (FDR) to adjust for multiple testing, fol-
lowing Newton et al. (2004) . Alternative FDR approaches
have been suggested by other authors ( Catelan et al., 2010;
Muller et al., 2006; Storey, 2003; Whittemore, 2007 ). Here,
we chose to adopt a standard classiﬁcation rule, as we be-
lieve that the above FDR rule does not apply in our case,
given the small number of positives we have. Besides, it is
argued whether there is a need to perform multiple test-
ing correction within a Bayesian framework ( Gelman et al.,
2012 ). 
Asthma and COPD are jointly considered in the analy-
sis, as the indication of the disease was not possible for
the prescriptions, and one of our objectives was to com-
pare between the different data sets. A next step is to sep-
arately explore asthma and COPD trends for all ages and
for children, adults and elderly to see if our ﬁndings hold
for these conditions individually, and to better understand
the temporal patterns of the areas found to be unusual.
Further analysis should formally investigate possible con-
founders, effect modiﬁers and causal factors such as de-
privation, smoking, seasonal respiratory virus activity and
service access, and to also adjust for socio-economic status,
as this is likely to affect the spatial patterns. It is relatively
easy to introduce covariates into the BaySTDetect model to
start to explore some of the hypotheses as to why some
CCGs differ from national trends. As an example we in-
troduced a variable to represent deprivation — the Index
of Multiple Deprivation (IMD) score, which was initially
available at LSOA level for England. This was aggregated at
CCG level, and then converted into a categorical variable of
5 levels (quintiles) which was introduced into the model
through dummy variables. The results showed no impor-
tant effect; the exponential of the posterior estimates ofthe coeﬃcients of the dummy variables varied from 0.99
to 1.02 with all credible intervals including 1. The inclusion
of deprivation in the model did not affect the posterior es-
timates of the other parameters, nor the areas that were
detected as unusual. 
In addition, a multivariate modelling approach will
be considered, which could provide a more comprehen-
sive picture of the trends and potential outbreaks of the
disease, by borrowing information across different data
sources. Finally, it would be useful to know the exact tem-
poral point at which an unusual observation occurs, and
the model should be modiﬁed to adjust for this. 
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